Comparative efficacy of subcutaneous (CT-P13) and intravenous infliximab in adult patients with rheumatoid arthritis: a network meta-regression of individual patient data from two randomised trials

BACKGROUND: A subcutaneous (SC) formulation of infliximab biosimilar CT-P13 is approved in Europe for the treatment of adult patients with rheumatoid arthritis (RA). It may offer improved efficacy versus intravenous (IV) infliximab formulations. METHODS: A network meta-regression was conducted using...

Descripción completa

Detalles Bibliográficos
Autores principales: Combe, Bernard, Allanore, Yannick, Alten, Rieke, Caporali, Roberto, Durez, Patrick, Iannone, Florenzo, Nurmohamed, Michael T., Toumi, Mondher, Lee, Sang Joon, Kwon, Taek Sang, Noh, Jiwon, Park, Gahee, Yoo, Dae Hyun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8051052/
https://www.ncbi.nlm.nih.gov/pubmed/33863352
http://dx.doi.org/10.1186/s13075-021-02487-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8051052/
https://www.ncbi.nlm.nih.gov/pubmed/33863352
http://dx.doi.org/10.1186/s13075-021-02487-x

Ejemplares similares